Cabaletta Bio to Present at Upcoming Investor Conferences in October
September 25, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences
September 08, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
August 25, 2020 08:00 ET
|
Cabaletta Bio
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgarisSoluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy...
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update
August 06, 2020 07:30 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio to Present at Multiple August Investor Conferences
August 03, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
July 07, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell...
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania
May 28, 2020 08:00 ET
|
Cabaletta Bio
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases PHILADELPHIA, May 28, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc....
Cabaletta Bio to Present at Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 27, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform
May 18, 2020 16:30 ET
|
Cabaletta Bio
In vivo preclinical data show that Chimeric AutoAntibody Receptor (CAAR) T cells were able to specifically recognize and eliminate anti-MuSK antibody-expressing B cells while sparing control B cells ...
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update
May 12, 2020 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...